Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Taylor TN, Farkouh RA, Graham JB, Colligs A, Lindemann M, Lynen R, Candrilli SD. Potential reduction in neural tube defects associated with use of metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol. 2011 Nov 1;205(5):460.e1-8.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Goyal RK, Patel JG, Sansgiry SS. Pharmacists perceptions of drug reimbursement rates and processing times among managed care plans. Drug benefit trends: a publication for manager and health professionals in hmos and ppos. 2010;22(4):116-20.